Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
CURE

How Recent Lung Cancer FDA Approvals are Shaping Treatment for Patients

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
TMCnet

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel ...

Phanes Therapeutics to Present Three Clinical Posters at AACR 2026

The US multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893) is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced ...
PharmiWeb

New Preclinical Data on Anti-Tumor Effects of Nadunolimab in Metastatic Colorectal Cancer Presented at the Keystone Cancer Immunotherapy Conference

LUND, SE / ACCESS Newswire / March 18, 2026 / Cantargia (STO:CANTA) today reported the presentation of new pre-clinical data highlighting how a murine surrogate antibody to nadunolimab, an anti-IL1RAP ...
Targeted Oncology

Trial Updates Influence Upfront Therapy Selection in Renal Cell Carcinoma

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...
Las Vegas Sun

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR ...

Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster ...

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.
Pharmabiz

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...
PharmiWeb

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...

Scientists Uncover Aging Link That Could Change How Cancer Is Treated

The researchers found higher ATF4 levels in tumors from older subjects, both in mice and in human patients. Elevated ATF4 was also linked to a greater chance of cancer returning after lung surgery and ...